Metacognitive Training Program With Depression

Terminated

• Conditions: Depression

• Registration Number: NCT02415426
• Lead Sponsor: Psychiatric University Hospital, Zurich

Brief Summary

The participants of this study have been diagnosed with mild to moderate depression with no evidence of suicidal actions prior to recruitment. All recruited subjects receive standard therapy and participate in a metacognitive training program (D-MKT) independently of study participation. Diagnostic and therapeutical interventions are not part of this study. As part of this study, the change of cognitive and psychosocial achievement/behavior in patients with mild to moderate depression after taking part in the training program is being investigated. The training program seeks to enable group members to recognize and correct the often automatic and unconscious thought patterns that accompany depression, in part by viewing this depressive thought process at a distance (i.e., depersonalizing). In addition, dysfunctional assumptions about one's thought processes, as well as dysfunctional coping-strategies (i.e., thought suppression, rumination as problem-solving) are targeted (Lena Jelinek \& Steffen Moritz, http://clinical-neuropsychology.de/metacognitive_training_for_depression.html). Within this study the cognitive and psychosocial behaviour changes are being investigated by neuropsychological assessment as well as questionnaires.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2015-03-26
• Study First Submitted QC: 2015-04-08
• Study First Posted: 2015-04-14
• Study Start: 2015-06
• Primary Completion: 2017-06
• Study Completion: 2017-06
• Status Verified: 2017-11
• Last Update Submitted: 2017-11-20
• Last Update Posted: 2017-11-21

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

• Participation in the Metacognitive Training Program
• Subjects with an age over 55 years and a diagnosed mild to moderate depression without psychotic Symptoms (F32, F33)
• Subjects have to be able to understand verbal and written information regarding treatment and procedures of the study.
• Subjects have to be able to understand and perform verbal and written tasks (cognitive tests/questionnaires).
• No evidence of suicidal tendency

Exclusion Criteria

• Taking of medication or drugs that could influence cognition
• Diseases that prevent the subject from giving consent to this study or affect the collaboration during the examination
• Major and/or unstable physical diseases
• Strongly impaired vision/eye diseases
• Psychotic or manic symptoms
• Benzodiazepine addiction/dependency
• Suicidal tendency

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Improvement of cognition as measured by Tower of London	14 months
Improvement of cognition as measured by Regensburger Wortflüssigkeitstest (RWT)	14 months
Improvement of depression as measured by Hamilton Depression Scale (HAMD)	14 months
Improvement of self-esteem as measured by Rosenberg Self-esteem Scale (RSE)	14 months
Improvement of depression as measured by Becks Depression Inventory (BDI)	14 months
Improvement of dysfunctional coping strategies as measured by Dysfunctional Attitude Scale (DAS)	14 months
Improvement of satisfaction and subjective well-being as measured by World Health Organization Quality of Life - short version (WHOQOL-BREF)	14 months
Improvement of cognition as measured by Verbaler Lern- und Merkfähigkeitstest (VLMT)	14 months
Improvement of cognition as measured by Consortium to Establish a Registry for Alzheimer's Disease (CERAD-Plus)	14 months
Improvement of cognition as measured by Wechsler Memory Scale Revised (WMS-R)	14 months
Improvement of cognition as measured by Cartoon Test	14 months
Improvement of cognition as measured by Faux Pas Test	14 months
Improvement of dysfunctional coping strategies as measured by 10-Item-Version of the Response Styles Questionnaire in German (RSQ-D)	14 months
Improvement of metacognitive thinking as measured by Metacognitions Questionnaire (MCQ)	14 months
Improvement of cognition as measured by 5-Point Test	14 months
Improvement of cognition as measured by MWT	14 months
Improvement of cognition as measured by Trail Making Test (TMT)	14 months
Improvement of cognition as measured by Wechsler Adult Intelligence Scale (WAIS-IV)	14 months
Improvement of cognition as measured by Testbatterie zur Aufmerksamkeitsprüfung (TAP)	14 months

Trial Locations

Locations (1)

Klinik für Alterspsychiatrie, Gerontopsychiatrisches Zentrum Hegibach; 🇨🇭 Zürich, Switzerland